TNFRSF8 and Hodgkins lymphoma: This is likely the reason why Auristatin E is extensively used in antibody-drug conjugates under development, one of which, Brentuximab vedotin, is currently used in the clinic to treat CD30+ Hodgkin’s lymphoma and anaplastic large-cell lymphoma patients [39].